Immune checkpoint inhibitors (ICIs) targeting the PD1/PDL1 axis have shown breakthrough efficacy in a variety of solid tumors, including advanced gastric cancer resistant to chemotherapy after multi-course treatment [3, 4]. This evidence concerns the gene PDCD1 and gastric cancer.